Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Chronic kidney disease

Last updated: November 30, 2020

Summarytoggle arrow icon

Chronic kidney disease (CKD) is defined as an abnormality of the kidney structure or function for ≥ 3 months. The most common causes of CKD in the United States are diabetes mellitus, hypertension, and glomerulonephritis. Since the kidneys have exceptional compensatory mechanisms, most patients remain asymptomatic and are unaware of their condition until their kidney function is significantly impaired. Patients typically present with symptoms of fluid overload (e.g., peripheral edema) and uremia. Laboratory evaluation shows hyperkalemia, hyperphosphatemia, and hypocalcemia, as well as metabolic acidosis. Management focuses mainly on treating the underlying disease and preventing possible complications, e.g., treating hypertension, avoiding nephrotoxic substances, and maintaining adequate hydration. If chronic kidney disease progresses to end-stage renal disease (ESRD), renal replacement therapy (dialysis) or a kidney transplant is necessary.

  • Chronic kidney disease is defined as an abnormality of the kidney structure or function for ≥ 3 months.

Associated with an irreversible reduction of the excretory (glomerular, tubular) and the endocrine functions of the kidney

References:[1]

  • About 10% of adults in the US suffer from chronic kidney disease.
  • African Americans are at increased risk of developing chronic kidney disease.

References:[2][3]

Epidemiological data refers to the US, unless otherwise specified.

Causes of CKD in the US
Diabetic nephropathy Most common cause, accounts for 44% of cases in the US
Hypertensive nephropathy 28%
Glomerulonephritis 8%
Polycystic kidney disease/hereditary 2%
Urological disease 0.5%
Other causes: amyloidosis, toxins, chronic inflammation

References:[3][4][5]

Patients develop secondary hyperparathyroidism and subsequent renal osteodystrophy due to hyperphosphatemia, hypocalcemia, and the insufficient production of vitamin D!

References:[6][7][8][9][10][11][12][13]

In chronic renal disease, close surveillance of serum potassium values as well as calcium and phosphate values is essential!References:[13][14][15][16]

References:[13][14][16][17][18][19][20][21][21]

Classification based on glomerular filtration rate

Stage Glomerular filtration rate (GFR) (mL/min/1.73 m2) Description
1 > 90 Normal or high
2 60 to 89 Mildly decreased
3 30 to 59 Moderately decreased
4 15 to 29 Severely decreased
5 < 15 Kidney failure

Classification based on albuminuria

Stage Urinary albumin excretion (mg/day) Description
A1 < 30 Normal
A2 30 to 300 Mildly increased (microalbuminuria)
A3 > 300 Severely increased (macroalbuminuria)

Interested in the newest medical research, distilled down to just one minute? Sign up for the One-Minute Telegram in “Tips and links” below.

  1. Levey AS, Inker LA. Definition and Staging of Chronic Kidney Disease in Adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/definition-and-staging-of-chronic-kidney-disease-in-adults.Last updated: November 16, 2016. Accessed: April 17, 2017.
  2. Papadakis MA, McPhee SJ, Rabow MW. CURRENT Medical Diagnosis and Treatment 2016. McGraw-Hill Education ; 2015
  3. National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2014. https://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf. Updated: January 1, 2014. Accessed: April 17, 2017.
  4. Goodman CC, Fuller KS. Pathology. Elsevier Health Sciences ; 2014
  5. 2015 Kidney Disease Statistics.
  6. Longmore M, Wilkinson IB, Davidson EH, Foulkes A, Mafi AR. Oxford Handbook of Clinical Medicine (2010). OUP Oxford ; 2010
  7. Mount DB. Treatment and Prevention of Hyperkalemia in Adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/treatment-and-prevention-of-hyperkalemia-in-adults.Last updated: September 29, 2016. Accessed: February 9, 2017.
  8. Goldman L, Schafer AI. Goldman-Cecil Medicine, 25th Edition. Elsevier ; 2016
  9. Greenberg A, National Kidney Foundation. Primer on Kidney Diseases. Academic Press ; 1994
  10. Quarles LD, Berkoben M. Management of Secondary Hyperparathyroidism and Mineral Metabolism Abnormalities in Dialysis Patients. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-and-mineral-metabolism-abnormalities-in-dialysis-patients.Last updated: February 2, 2017. Accessed: April 17, 2017.
  11. Black RM. Pericarditis in Renal Failure. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/pericarditis-in-renal-failure.Last updated: June 9, 2015. Accessed: April 17, 2017.
  12. Qunibi WY, Henrich WL. Overview of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd.Last updated: January 19, 2017. Accessed: April 18, 2017.
  13. Berns JS, Coutre S. Platelet Dysfunction in Uremia. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/platelet-dysfunction-in-uremia.Last updated: June 26, 2015. Accessed: April 18, 2017.
  14. Rosenberg M. Overview of the Management of Chronic Kidney Disease in Adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/overview-of-the-management-of-chronic-kidney-disease-in-adults.Last updated: February 24, 2016. Accessed: April 18, 2017.
  15. Arora P. Chronic Kidney Disease. Chronic Kidney Disease. New York, NY: WebMD. http://emedicine.medscape.com/article/238798. Updated: July 24, 2016. Accessed: April 18, 2017.
  16. Berns JS. Hyporesponse to Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/hyporesponse-to-erythropoiesis-stimulating-agents-esas-in-chronic-kidney-disease.Last updated: January 13, 2017. Accessed: January 4, 2018.
  17. Decker BS, Molitoris BA. Manifestations of and Risk Factors for Aminoglycoside Nephrotoxicity. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/manifestations-of-and-risk-factors-for-aminoglycoside-nephrotoxicity.Last updated: May 21, 2015. Accessed: April 18, 2017.
  18. Portilla D, Safar M, Shannon ML, Penson RT. Cisplatin Nephrotoxicity. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/cisplatin-nephrotoxicity.Last updated: December 15, 2016. Accessed: April 18, 2017.
  19. Sterns RH. Amphotericin B Nephrotoxicity. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/amphotericin-b-nephrotoxicity.Last updated: December 3, 2015. Accessed: April 18, 2017.
  20. Weaver VM, Jaar BG. Lead nephropathy and lead-related nephrotoxicity. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/lead-nephropathy-and-lead-related-nephrotoxicity.Last updated: March 22, 2017. Accessed: April 18, 2017.
  21. Hahr AJ, Molitch ME. Management of diabetes mellitus in patients with chronic kidney disease. Clin Diabetes Endocrinol. 2015; 1 (1). doi: 10.1186/s40842-015-0001-9 . | Open in Read by QxMD
  22. Guideline summary: KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. https://www.guideline.gov/summaries/summary/39430?search=chronic%20kidney%20disease. Updated: December 1, 2012. Accessed: April 17, 2017.
  23. Chronic Kidney Disease. http://5minuteconsult.com/collectioncontent/1-151514/diseases-and-conditions/chronic-kidney-disease. Updated: July 1, 2016. Accessed: April 18, 2017.
  24. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States..